Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: Treatment concept to correct diabetes-associated deficits

Sergio Li Calzi, Matthew B. Neu, Lynn C. Shaw, Maria B. Grant

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Progressive obliteration of the retinal microvessels is a characteristic of diabetic retinopathy and the resultant retinal ischemia can lead to sight-threatening macular edema, macular ischemia and ultimately preretinal neovascularization. Bone marrow derived endothelial progenitor cells (EPCs) play a critical role in vascular maintenance and repair. There is still great debate about the most appropriate markers that define an EPC. EPCs can be isolated using cell sorting by surface phenotype selection or in vitro cell culture. For freshly isolated cells, EPC cell sorting is heavily dependent on the surface markers used; EPCs can also be isolated by in vitro propagation of heterogeneous mixtures of cells in culture using adhesion to specific substrates and cell growth characteristics. in vitro isolation enables consistent reproducibility and using this approach at least two distinct types of EPCs with different angiogenic properties have been identified from adult peripheral and umbilical cord blood; early EPCs (eEPCs) and late outgrowth endothelial progenitor cells (OECs). Emerging studies demonstrate the potential of these cells in revascularization of ischemic/injured retina in animal models of retinal disease. Since ischemic retinopathies are leading causes of blindness, they are a potential disease target for EPC-based therapy. In this chapter, we summarize the current knowledge about EPCs and discuss the possibility of cellular therapy for treatment of diabetic macular ischemia and the vasodegenerative phase of diabetic retinopathy. We also report current pharmacological options that can be utilized to correct diabetes associated defects in EPCs so as to enhance the therapeutic utility of these cells.

Original languageEnglish (US)
Pages (from-to)88-100
Number of pages13
JournalEPMA Journal
Volume1
Issue number1
DOIs
StatePublished - Mar 2010
Externally publishedYes

Fingerprint

Endothelial cells
Diabetic Retinopathy
Medical problems
Therapeutics
Ischemia
Sorting
Cell culture
Cell Culture Techniques
Cells
Endothelial Progenitor Cells
Retinal Diseases
Macular Edema
Cell growth
Blindness
Cell- and Tissue-Based Therapy
Microvessels
Fetal Blood
Blood Vessels
Retina
Bone

Keywords

  • Adult stem cells
  • Angiogenesis
  • Diabetic retinopathy
  • Endothelial progenitor cells
  • Ischemia targeted treatment

ASJC Scopus subject areas

  • Health Policy
  • Biochemistry, medical
  • Drug Discovery

Cite this

Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy : Treatment concept to correct diabetes-associated deficits. / Calzi, Sergio Li; Neu, Matthew B.; Shaw, Lynn C.; Grant, Maria B.

In: EPMA Journal, Vol. 1, No. 1, 03.2010, p. 88-100.

Research output: Contribution to journalArticle

Calzi, Sergio Li ; Neu, Matthew B. ; Shaw, Lynn C. ; Grant, Maria B. / Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy : Treatment concept to correct diabetes-associated deficits. In: EPMA Journal. 2010 ; Vol. 1, No. 1. pp. 88-100.
@article{e5de43f2cd4d471596f7c0b9506cbe14,
title = "Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy: Treatment concept to correct diabetes-associated deficits",
abstract = "Progressive obliteration of the retinal microvessels is a characteristic of diabetic retinopathy and the resultant retinal ischemia can lead to sight-threatening macular edema, macular ischemia and ultimately preretinal neovascularization. Bone marrow derived endothelial progenitor cells (EPCs) play a critical role in vascular maintenance and repair. There is still great debate about the most appropriate markers that define an EPC. EPCs can be isolated using cell sorting by surface phenotype selection or in vitro cell culture. For freshly isolated cells, EPC cell sorting is heavily dependent on the surface markers used; EPCs can also be isolated by in vitro propagation of heterogeneous mixtures of cells in culture using adhesion to specific substrates and cell growth characteristics. in vitro isolation enables consistent reproducibility and using this approach at least two distinct types of EPCs with different angiogenic properties have been identified from adult peripheral and umbilical cord blood; early EPCs (eEPCs) and late outgrowth endothelial progenitor cells (OECs). Emerging studies demonstrate the potential of these cells in revascularization of ischemic/injured retina in animal models of retinal disease. Since ischemic retinopathies are leading causes of blindness, they are a potential disease target for EPC-based therapy. In this chapter, we summarize the current knowledge about EPCs and discuss the possibility of cellular therapy for treatment of diabetic macular ischemia and the vasodegenerative phase of diabetic retinopathy. We also report current pharmacological options that can be utilized to correct diabetes associated defects in EPCs so as to enhance the therapeutic utility of these cells.",
keywords = "Adult stem cells, Angiogenesis, Diabetic retinopathy, Endothelial progenitor cells, Ischemia targeted treatment",
author = "Calzi, {Sergio Li} and Neu, {Matthew B.} and Shaw, {Lynn C.} and Grant, {Maria B.}",
year = "2010",
month = "3",
doi = "10.1007/s13167-010-0011-8",
language = "English (US)",
volume = "1",
pages = "88--100",
journal = "EPMA Journal",
issn = "1878-5077",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Endothelial progenitor dysfunction in the pathogenesis of diabetic retinopathy

T2 - Treatment concept to correct diabetes-associated deficits

AU - Calzi, Sergio Li

AU - Neu, Matthew B.

AU - Shaw, Lynn C.

AU - Grant, Maria B.

PY - 2010/3

Y1 - 2010/3

N2 - Progressive obliteration of the retinal microvessels is a characteristic of diabetic retinopathy and the resultant retinal ischemia can lead to sight-threatening macular edema, macular ischemia and ultimately preretinal neovascularization. Bone marrow derived endothelial progenitor cells (EPCs) play a critical role in vascular maintenance and repair. There is still great debate about the most appropriate markers that define an EPC. EPCs can be isolated using cell sorting by surface phenotype selection or in vitro cell culture. For freshly isolated cells, EPC cell sorting is heavily dependent on the surface markers used; EPCs can also be isolated by in vitro propagation of heterogeneous mixtures of cells in culture using adhesion to specific substrates and cell growth characteristics. in vitro isolation enables consistent reproducibility and using this approach at least two distinct types of EPCs with different angiogenic properties have been identified from adult peripheral and umbilical cord blood; early EPCs (eEPCs) and late outgrowth endothelial progenitor cells (OECs). Emerging studies demonstrate the potential of these cells in revascularization of ischemic/injured retina in animal models of retinal disease. Since ischemic retinopathies are leading causes of blindness, they are a potential disease target for EPC-based therapy. In this chapter, we summarize the current knowledge about EPCs and discuss the possibility of cellular therapy for treatment of diabetic macular ischemia and the vasodegenerative phase of diabetic retinopathy. We also report current pharmacological options that can be utilized to correct diabetes associated defects in EPCs so as to enhance the therapeutic utility of these cells.

AB - Progressive obliteration of the retinal microvessels is a characteristic of diabetic retinopathy and the resultant retinal ischemia can lead to sight-threatening macular edema, macular ischemia and ultimately preretinal neovascularization. Bone marrow derived endothelial progenitor cells (EPCs) play a critical role in vascular maintenance and repair. There is still great debate about the most appropriate markers that define an EPC. EPCs can be isolated using cell sorting by surface phenotype selection or in vitro cell culture. For freshly isolated cells, EPC cell sorting is heavily dependent on the surface markers used; EPCs can also be isolated by in vitro propagation of heterogeneous mixtures of cells in culture using adhesion to specific substrates and cell growth characteristics. in vitro isolation enables consistent reproducibility and using this approach at least two distinct types of EPCs with different angiogenic properties have been identified from adult peripheral and umbilical cord blood; early EPCs (eEPCs) and late outgrowth endothelial progenitor cells (OECs). Emerging studies demonstrate the potential of these cells in revascularization of ischemic/injured retina in animal models of retinal disease. Since ischemic retinopathies are leading causes of blindness, they are a potential disease target for EPC-based therapy. In this chapter, we summarize the current knowledge about EPCs and discuss the possibility of cellular therapy for treatment of diabetic macular ischemia and the vasodegenerative phase of diabetic retinopathy. We also report current pharmacological options that can be utilized to correct diabetes associated defects in EPCs so as to enhance the therapeutic utility of these cells.

KW - Adult stem cells

KW - Angiogenesis

KW - Diabetic retinopathy

KW - Endothelial progenitor cells

KW - Ischemia targeted treatment

UR - http://www.scopus.com/inward/record.url?scp=79960049458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960049458&partnerID=8YFLogxK

U2 - 10.1007/s13167-010-0011-8

DO - 10.1007/s13167-010-0011-8

M3 - Article

AN - SCOPUS:79960049458

VL - 1

SP - 88

EP - 100

JO - EPMA Journal

JF - EPMA Journal

SN - 1878-5077

IS - 1

ER -